Genaissance Begins Enrolling Patients for Haplotype Studies | GenomeWeb

NEW YORK, April 24 - Genaissance Pharmaceuticals said Tuesday it had begun enrolling patients for its clinical trials which will aim to correlate haplotypes with individuals’ reactions to particular drugs.

In its initial study, the company plans to enroll about 600 patients at 60 medical centers in the US to correlate patient haplotypes with the affects of cholesterol lowering drugs. The Statin Response Examined by Genetic HAP Study, or STRENGTH, will look at Lipitor, Zocor, Pravachol, and Baycol. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.